Targeted therapy of cancer: new roles for pathologists in colorectal cancer
- 1 May 2008
- journal article
- review article
- Published by Elsevier in Laboratory Investigation
- Vol. 21, S23-S30
- https://doi.org/10.1038/modpathol.2008.14
Abstract
No abstract availableKeywords
This publication has 59 references indexed in Scilit:
- Cetuximab Shows Activity in Colorectal Cancer Patients With Tumors for Which FISH Analysis Does Not Detect an Increase in EGFR Gene Copy NumberAnnals of Surgical Oncology, 2007
- Association between DNA Methylation and Shortened Survival in Patients with Advanced Colorectal Cancer Treated with 5-Fluorouracil–Based ChemotherapyClinical Cancer Research, 2007
- Current status of excision repair cross complementing-group 1 (ERCC1) in cancerCancer Treatment Reviews, 2007
- Irinotecan in the treatment of colorectal cancerCancer Treatment Reviews, 2006
- Lymph Node Status and TS Gene Expression Are Prognostic Markers in Stage II/III Rectal Cancer After Neoadjuvant Fluorouracil-Based ChemoradiotherapyJournal of Clinical Oncology, 2006
- Predicting the outcome of chemotherapy for colorectal cancerCurrent Opinion in Pharmacology, 2006
- Predicting 5‐fluorouracil chemosensitivity of liver metastases from colorectal cancer using primary tumor specimens: Three‐gene expression model predicts clinical responseInternational Journal of Cancer, 2006
- Adjuvant therapy in colon cancer—what, when and how?Annals of Oncology, 2006
- How may Anticancer Chemotherapy with Fluorouracil be Individualised?Clinical Pharmacokinetics, 2006
- Thymidylate synthase pharmacogeneticsInvestigational New Drugs, 2005